8-K
filed June 11, 2026, 5:23 PM ET
ticker PALI
CIK 0001357459
other material
confidence high
sentiment neutral
materiality 0.55
Palisade Bio appoints Jordan Zwick to board; shareholders approve 50% share increase to 450M
PALISADE BIO, INC.
- Jordan Zwick appointed to board, effective June 10, 2026; board expanded from five to six members.
- Zwick received initial RSU grant of $566,000, vesting in three equal annual installments.
- Stockholders approved amendment to increase authorized common shares from 300M to 450M, effective June 11, 2026.
- Stockholders approved Amended and Restated 2021 Equity Incentive Plan (42.257M shares) and Employee Stock Purchase Plan.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jordan Zwick was appointed as Director at PALISADE BIO, INC..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 10, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Palisade Bio, Inc. (the “Company”) expanded the size of the Board from five to six directors and appointed Jordan Zwick to the Board.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
PALISADE BIO, INC.: Increased authorized shares of common stock from 300,000,000 to 450,000,000 via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2026-06-11).
- Change
- charter amendment
- Effective
- 2026-06-11
Exact text from the filing
On June 11, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2026-06-10 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 (which will result in an increase in the total number of authorized shares of capital stock of the Company from 307,000,000 to 457,000,000).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Approval of the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan at the 2026-06-10 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Election of Directors at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders elected the four (4) persons listed below as directors, each to serve until the Company’s 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Approval of equity award grants to our non-employee directors at the 2026-06-10 meeting.
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders approved equity grants to the Company’s non-employee directors.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders ratified the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PALISADE BIO, INC. shareholders approved Approval of the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan at the 2026-06-10 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
The Company’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.